Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends.

Issa AM, Phillips KA, Van Bebber S, Nidamarthy HG, Lasser KE, Haas JS, Alldredge BK, Wachter RM, Bates DW.

Curr Drug Saf. 2007 Sep;2(3):177-85. Review.

PMID:
18690965
2.

Timing of new black box warnings and withdrawals for prescription medications.

Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH.

JAMA. 2002 May 1;287(17):2215-20.

PMID:
11980521
3.

Drug withdrawals from the Canadian market for safety reasons, 1963-2004.

Lexchin J.

CMAJ. 2005 Mar 15;172(6):765-7. No abstract available.

4.

Adverse drug reactions in elderly patients: alternative approaches to postmarket surveillance.

Noah BA, Brushwood DB.

J Health Law. 2000 Summer;33(3):383-454.

PMID:
11184355
5.

Impact of regulatory guidances and drug regulation on risk minimization interventions in drug safety: a systematic review.

Nkeng L, Cloutier AM, Craig C, Lelorier J, Moride Y.

Drug Saf. 2012 Jul 1;35(7):535-46. doi: 10.2165/11599720-000000000-00000. Review.

PMID:
22702638
6.

Evaluation of FDA safety-related drug label changes in 2010.

Lester J, Neyarapally GA, Lipowski E, Graham CF, Hall M, Dal Pan G.

Pharmacoepidemiol Drug Saf. 2013 Mar;22(3):302-5. doi: 10.1002/pds.3395. Epub 2013 Jan 2.

PMID:
23280652
7.

The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France.

Olivier P, Montastruc JL.

Pharmacoepidemiol Drug Saf. 2006 Nov;15(11):808-12.

PMID:
16700082
8.
9.

Era of faster FDA drug approval has also seen increased black-box warnings and market withdrawals.

Frank C, Himmelstein DU, Woolhandler S, Bor DH, Wolfe SM, Heymann O, Zallman L, Lasser KE.

Health Aff (Millwood). 2014 Aug;33(8):1453-9. doi: 10.1377/hlthaff.2014.0122.

10.

Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature.

Onakpoya IJ, Heneghan CJ, Aronson JK.

BMC Med. 2016 Feb 4;14:10. doi: 10.1186/s12916-016-0553-2. Review.

11.

Can pharmacogenetics help rescue drugs withdrawn from the market?

Shah RR.

Pharmacogenomics. 2006 Sep;7(6):889-908. Review.

PMID:
16981848
12.

Safety of newly approved drugs: implications for prescribing.

Temple RJ, Himmel MH.

JAMA. 2002 May 1;287(17):2273-5. No abstract available.

PMID:
11980528
13.

Consistency in the safety labeling of bioequivalent medications.

Duke J, Friedlin J, Li X.

Pharmacoepidemiol Drug Saf. 2013 Mar;22(3):294-301. doi: 10.1002/pds.3351. Epub 2012 Oct 8.

PMID:
23042584
14.

A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009.

Mol PG, Straus SM, Piening S, de Vries JT, de Graeff PA, Haaijer-Ruskamp FM.

Drug Saf. 2010 Jun 1;33(6):463-74. doi: 10.2165/11532840-000000000-00000.

PMID:
20486729
15.

Assessing drug safety and consequences of drug withdrawals.

Mamdani M.

J Am Pharm Assoc (2003). 2004 Nov-Dec;44(6):659-60. No abstract available.

PMID:
15637847
17.

New drug approval times and safety warnings in the United States and Canada, 1992-2011.

Rawson NS.

J Popul Ther Clin Pharmacol. 2013;20(2):e67-81. Epub 2013 Apr 22.

PMID:
23650206
18.

The credibility of the FDA.

Blankfield RP.

Eur J Prev Cardiol. 2013 Dec;20(6):992-4. doi: 10.1177/2047487313497605. Epub 2013 Jul 18. No abstract available.

PMID:
23867140
19.

Preventing postmarketing changes in recommended doses and marketing withdrawals.

Peck C.

Ernst Schering Res Found Workshop. 2007;(59):209-16. Review.

PMID:
17117726
20.

The use of evidence in pharmacovigilance. Case reports as the reference source for drug withdrawals.

Arnaiz JA, Carné X, Riba N, Codina C, Ribas J, Trilla A.

Eur J Clin Pharmacol. 2001 Apr;57(1):89-91. Review.

PMID:
11372600

Supplemental Content

Support Center